Abstract
Antidepressants are an effective treatment for major depressive disorder (MDD), although individual response is unpredictable and highly variable. Whilst the mode of action of antidepressants is incompletely understood, many medications are associated with changes in DNA methylation in genes that are plausibly linked to their mechanisms. Studies of DNA methylation may therefore reveal the biological processes underpinning the efficacy and side effects of antidepressants.
We performed a methylome-wide association study (MWAS) of self-reported antidepressant use accounting for lifestyle factors and MDD in Generation Scotland (GS:SFHS, N=6,428, EPIC array) and the Netherlands Twin Register (NTR, N=2,449, 450K array) and ran a meta-analysis of antidepressant use across these two cohorts.
We found 10 CpG sites significantly associated with self-reported antidepressant use in GS:SFHS, with the top CpG located within a gene previously associated with mental health disorders, ATP6V1B2 (β=-0.055, pcorrected=0.005). Other top loci were annotated to genes including CASP10, TMBIM1, MAPKAPK3, and HEBP2, which have previously been implicated in the innate immune response. Next, using penalised regression, we trained a methylation-based score of self-reported antidepressant use in a subset of 3,799 GS:SFHS individuals that predicted antidepressant use in a second subset of GS:SFHS (N=3,360, β=0.377, p=3.12×10−11, R2=2.12%). In an MWAS analysis of prescribed selective serotonin reuptake inhibitors, we showed convergent findings with those based on self-report. In NTR, we did not find any CpGs significantly associated with antidepressant use. The meta-analysis identified the two CpGs of the ten above that were common to the two arrays used as being significantly associated with antidepressant use, although the effect was in the opposite direction for one of them.
Antidepressants were associated with epigenetic alterations in loci previously associated with mental health disorders and the innate immune system. These changes predicted self-reported antidepressant use in a subset of GS:SFHS and identified processes that may be relevant to our mechanistic understanding of clinically relevant antidepressant drug actions and side effects.
Competing Interest Statement
AMM has previously received grant support from Pfizer, Lilly and Janssen. These studies are not connected to the current investigation. Remaining authors report no conflicts of interest.
Funding Statement
Generation Scotland is currently supported by the Wellcome Trust Investigator Award in Science 01/06/2021 to 31/05/26 "Exploiting genomic approaches to identify the environmental basis of depression". (Reference: 220857/Z/20/Z) to McIntosh AM (PI). The DNA methylation profiling and data preparation was supported by Wellcome Investigator Award 220857/Z/20/Z and Grant 104036/Z/14/Z (PI for both grants: McIntosh AM) and through funding from NARSAD (Ref: 27404; PI: Dr DM Howard and Ref: 21956; PI: Dr Kathryn Evans) and the Royal College of Physicians of Edinburgh (Sim Fellowship; PI: Dr HC Whalley). Dr CA was supported by an MRC University Unit award to the MRC Human Genetics Unit, University of Edinburgh, MC_UU_00007/10. Genotyping of the GS:SFHS samples was funded by the MRC and Wellcome Trust [104036/Z/14/Z]. Generation Scotland also receives support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Dr DMH is supported by a Sir Henry Wellcome Postdoctoral Fellowship (Reference 213674/Z/18/Z). Dr MCB is supported by a Guarantors of Brain Non-clinical Post-Doctoral Fellowship. Dr EB is an NIHR Senior Investigator and is a member of the scientific advisory board of Sosei Heptares. Dr ML is supported by a fellowship from the Medical Research Council (MR/S006257/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
GS:SFHS received ethical approval from NHS Tayside Research Ethics Committee (REC reference number 05/S1401/89) and has Research Tissue Bank Status (reference: 20/ES/0021). Written informed consent was obtained from all participants. The study was approved by the Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Centre, Amsterdam, an Institutional Review Board certified by the U.S. Office of Human Research Protections (IRB number IRB00002991 under Federal-wide Assurance- FWA00017598; IRB/institute codes, NTR 03-180).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We included further analyses of the data (i.e. differential methylation analysis). We have also included a second cohort in the study (the Netherlands Twin Register) in order to carry out a meta-analysis.
Data Availability
Data is available upon request, contacting individuals here: https://www.ed.ac.uk/generation-scotland
